{"id":"avatrombopag-tablets","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Headache"},{"rate":"6%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Avatrombopag works by binding to and activating the thrombopoietin receptor, stimulating platelet production.","oneSentence":"Thrombopoietin receptor agonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:05.526Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombocytopenia"}]},"trialDetails":[{"nctId":"NCT05772546","phase":"PHASE2","title":"Avatrombopag vs. Placebo for CIT in GI Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanny Al-Samkari, MD","startDate":"2023-11-01","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia","enrollment":60},{"nctId":"NCT04516967","phase":"PHASE3","title":"Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months","status":"COMPLETED","sponsor":"Sobi, Inc.","startDate":"2021-03-05","conditions":"Immune Thrombocytopenia","enrollment":75},{"nctId":"NCT05369208","phase":"PHASE3","title":"Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP","status":"COMPLETED","sponsor":"Sobi, Inc.","startDate":"2022-06-15","conditions":"Immune Thrombocytopenia","enrollment":19},{"nctId":"NCT07051915","phase":"PHASE3","title":"The Holistic Study","status":"NOT_YET_RECRUITING","sponsor":"Ostfold Hospital Trust","startDate":"2025-09-15","conditions":"Thrombocytopenia Purpura","enrollment":220},{"nctId":"NCT07133659","phase":"PHASE4","title":"Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study","status":"RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-06-08","conditions":"ITP - Immune Thrombocytopenia","enrollment":25},{"nctId":"NCT04638829","phase":"PHASE4","title":"Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim","status":"COMPLETED","sponsor":"Sobi, Inc.","startDate":"2021-03-15","conditions":"Immune Thrombocytopenia","enrollment":60},{"nctId":"NCT03471078","phase":"PHASE3","title":"Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers","status":"COMPLETED","sponsor":"Sobi, Inc.","startDate":"2018-10-12","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":122},{"nctId":"NCT04915287","phase":"PHASE4","title":"Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-06-06","conditions":"Thrombocytopenia; Drugs, Chronic Liver Disease","enrollment":476},{"nctId":"NCT05571332","phase":"NA","title":"Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-28","conditions":"Aplastic Anemia","enrollment":39},{"nctId":"NCT04609891","phase":"NA","title":"Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors","status":"COMPLETED","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2020-05-26","conditions":"Thrombocytopenia","enrollment":74},{"nctId":"NCT05046327","phase":"PHASE3","title":"Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months","status":"WITHDRAWN","sponsor":"Sobi, Inc.","startDate":"2021-10-14","conditions":"Immune Thrombocytopenia","enrollment":""},{"nctId":"NCT02227693","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2014-07","conditions":"Thrombocytopenia Associated With Chronic Liver Disease","enrollment":39},{"nctId":"NCT00625443","phase":"PHASE2","title":"Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-05","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":53},{"nctId":"NCT00441090","phase":"PHASE2","title":"Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-02","conditions":"Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic","enrollment":64},{"nctId":"NCT01972529","phase":"PHASE3","title":"Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2014-02","conditions":"Thrombocytopenia Associated With Liver Disease","enrollment":231},{"nctId":"NCT01976104","phase":"PHASE3","title":"Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2013-11","conditions":"Thrombocytopenia Associated With Liver Disease","enrollment":204},{"nctId":"NCT00914927","phase":"PHASE2","title":"Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2009-05","conditions":"Thrombocytopenia Related to Chronic Liver Disease","enrollment":130},{"nctId":"NCT01260155","phase":"PHASE1","title":"A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2010-01","conditions":"Healthy Subjects","enrollment":16},{"nctId":"NCT01289509","phase":"PHASE1","title":"A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2010-12","conditions":"Idiopathic Thrombocytopenia Purpura","enrollment":42},{"nctId":"NCT01759394","phase":"PHASE1","title":"A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-10","conditions":"Healthy Volunteers","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AKR-501","E5501","YM477"],"phase":"phase_2","status":"active","brandName":"Avatrombopag tablets","genericName":"Avatrombopag tablets","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Avatrombopag tablets are a small molecule thrombopoietin receptor agonist, classified as an agonist. They are used to treat conditions such as chemotherapy-induced thrombocytopenia, immune thrombocytopenia, and idiopathic thrombocytopenia purpura.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}